###begin article-title 0
###xml 10 15 10 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</bold>
###xml 10 15 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><bold>&#945;</bold></italic>
###xml 43 47 39 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 43 47 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><bold>&#946;</bold></italic>
###xml 33 37 <span type="species:ncbi:10090">Mice</span>
###xml 80 85 <span type="species:ncbi:9606">Human</span>
Disturbed alpha-Cell Function in Mice with beta-Cell Specific Overexpression of Human Islet Amyloid Polypeptide
###end article-title 0
###begin p 1
Recommended by Per Westermark
###end p 1
###begin p 2
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 144 149 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 177 181 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 365 366 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 416 417 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 423 424 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 608 609 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 770 771 755 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1129 1133 1114 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 214 219 <span type="species:ncbi:9606">human</span>
###xml 282 287 <span type="species:ncbi:10090">mouse</span>
###xml 330 345 <span type="species:ncbi:10090">transgenic mice</span>
###xml 536 551 <span type="species:ncbi:10090">transgenic mice</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
###xml 949 954 <span type="species:ncbi:10090">mouse</span>
###xml 1052 1056 <span type="species:ncbi:10090">mice</span>
###xml 1119 1123 <span type="species:ncbi:10090">mice</span>
###xml 1166 1171 <span type="species:ncbi:9606">human</span>
Exogenous administration of islet amyloid polypeptide (IAPP) has been shown to inhibit both insulin and glucagon secretion. This study examined alpha-cell function in mice with beta-cell specific overexpression of human IAPP (hIAPP) after an oral protein gavage (75 mg whey protein/mouse). Baseline glucagon levels were higher in transgenic mice (41 +/- 4.0 pg/mL, n = 6) than in wildtype animals (19 +/- 5.1 pg/mL, n = 5, P = .015). In contrast, the glucagon response to protein was impaired in transgenic animals (21 +/- 2.7 pg/mL in transgenic mice versus 38 +/- 5.7 pg/mL in wildtype mice at 15 minutes; P = .027). Baseline insulin levels did not differ between the groups, while the insulin response, as the glucagon response, was impaired after protein challenge (P = .018). Glucose levels were not different between the groups and did not change significantly after protein gavage. Acetaminophen was given through gavage to the animals (2 mg/mouse) to estimate gastric emptying. The plasma acetaminophen profile was similar in the two groups of mice. We conclude that disturbances in glucagon secretion exist in mice with beta-cell specific overexpression of human IAPP, which are not secondary to changes in gastric emptying. The reduced glucagon response to protein challenge may reflect a direct inhibitory influence of hIAPP on glucagon secretion.
###end p 3
###begin title 4
1. INTRODUCTION
###end title 4
###begin p 5
###xml 79 83 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 116 117 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 118 119 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 153 154 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 222 223 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 225 226 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 228 229 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 230 231 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 361 362 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 363 365 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 480 484 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 516 518 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 519 521 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 564 568 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 738 743 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 751 753 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 755 757 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1046 1048 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1182 1184 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 380 385 <span type="species:ncbi:9606">human</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
###xml 605 610 <span type="species:ncbi:9606">human</span>
###xml 774 778 <span type="species:ncbi:10090">mice</span>
###xml 959 963 <span type="species:ncbi:10090">mice</span>
###xml 985 989 <span type="species:ncbi:10090">mice</span>
###xml 1113 1117 <span type="species:ncbi:10090">mice</span>
Islet amyloid polypeptide is a 37-amino-acid peptide, which is produced in the beta-cells in the pancreatic islets [1-3]. It is coreleased with insulin [4], and exogenous administration of IAPP inhibits insulin secretion [2, 3, 5-7]. Several studies have also shown that exogenous administration of IAPP at supraphysiological doses inhibits glucagon secretion [8-11]. IAPP of the human form may lead to fibril formation, which causes amyloid deposition in the islets resulting in beta-cell dysfunction and diabetes [12-14]. We have previously shown that mice with beta-cell specific overexpression of the human form of IAPP (hIAPP) have defective insulin secretion and disturbed islet topography with centrally located glucagon producing alpha-cells [15, 16]. Whether these mice in addition have disturbed glucagon secretion is, however, not known. Therefore, the aim of the present study was to examine the glucagon response to an oral protein load in these mice compared to wildtype mice. Since IAPP has been shown to inhibit gastric emptying [11], also the gastric emptying rate in the transgenic and wildtype mice was evaluated with the previously described acetaminophen-test [17], to control for any differences in gastric emptying between the groups.
###end p 5
###begin title 6
2. METHODS
###end title 6
###begin title 7
2.1. Animals
###end title 7
###begin p 8
###xml 38 42 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 141 143 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 254 256 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 11 26 <span type="species:ncbi:10090">transgenic mice</span>
###xml 263 278 <span type="species:ncbi:10090">transgenic mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
Hemizygous transgenic mice with islet beta-cell expression of hIAPP on a C57BL/6J/6xDBA/2 background were generated as previously described [18]. Transgenic status was determined by PCR using oligonucleotide primers directed against the hIAPP transgene [19]. The transgenic mice and their wildtype controls were kind gifts of Dr Steven E Kahn, University of Washington, Seattle, Wash, USA. Transgenic and wildtype mice were transported from the animal facility of the University of Washington, Seattle, to the In Vivo Department, Biomedical Center, Lund University, Lund, Sweden, after embryo transfer performed at Taconic A/S, Ry, Denmark. The animals were cross-bred for >16 generations to C57BL/6J mice. The animals were kept in a 12-hour light schedule (lights on at 0600 am) and given a standard pellet diet (fat 11.4%, carbohydrate 62.8%, protein 25.8% on an energy base, total energy 12.6 kJ/g) and tap water ad libitum. The Ethics Committee in Lund/Malmo approved the study.
###end p 8
###begin title 9
2.2. Experiments
###end title 9
###begin p 10
###xml 662 664 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 786 788 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 861 863 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 279 284 <span type="species:ncbi:10090">mouse</span>
###xml 308 313 <span type="species:ncbi:10090">mouse</span>
Following a four-hour period after removal of food from the cage, female transgenic and wildtype animals were anesthetized with an intraperitoneal injection of midazolam (Dormicum, Hoffman-La-Roche, Basel, Switzerland, 0.2 mg/mouse) as well as a combination of fluanison (0.4 mg/mouse) and fentanyl (0.02 mg/mouse; Hypnorm, Janssen, Beerse, Belgium). Thirty minutes later, a blood sample was taken from the retrobulbar, intraorbital, capillary plexus in heparinized tubes. Then, whey protein (100% Anywhey, 75 mg, Optimum Nutrition, Lindesberg, Sweden) and acetaminophen (paracetamol; Sigma Chemical Co, St Louis, Mo, 2 mg) dissolved in saline (total volume 500 muL) were administered through a gastric tube (outer diameter 1.2 mm). After 15, 30, 60, and 120 minutes, blood samples, 75 muL each, were collected. Blood was kept in heparinized tubes containing 5 muL Trasylol (aprotinin; 10000 KIE/mL; Bayer HealthCare AG, Leverkusen, Germany), immediately centrifuged whereupon plasma was separated and stored at -20degreesC until analysis for glucose, glucagon, insulin, and acetaminophen.
###end p 10
###begin title 11
2.3. Analyses
###end title 11
###begin p 12
###xml 93 103 <span type="species:ncbi:10141">guinea pig</span>
###xml 371 381 <span type="species:ncbi:10141">guinea pig</span>
###xml 429 434 <span type="species:ncbi:9606">human</span>
###xml 457 460 <span type="species:ncbi:10116">rat</span>
Plasma glucagon was determined with radioimmunoassay (Linco Res, St Charles, Mo, USA) with a guinea pig antiglucagon antibody, radioiodine labelled glucagon as tracer and glucagon standard. CV of the assay is 8% and the sensitivity of the assay is 10 pg/mL. The antibodies do not cross-react with GLP-1. Plasma insulin was determined with radioimmunoassay (Linco) with a guinea pig antirat insulin antibody, radioiodine labelled human insulin as tracer and rat insulin as standard. Plasma acetaminophen was determined with a colorimetric assay (Cambridge Life Science, Ely, Cambridgeshire, UK). Plasma glucose was determined with the glucose oxidase method.
###end p 12
###begin title 13
2.4. Calculations and statistics
###end title 13
###begin p 14
###xml 83 84 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Means +/- SEM are shown. Statistical comparisons were performed with the Student's t-test. For estimation of glucagon secretion, the increase in plasma glucagon levels during the first 15 minutes after protein gavage was estimated by subtracting baseline glucagon values from the 15-minute glucagon values. The area under the glucagon and insulin curves (AUCs) were also calculated using the trapezoid rule.
###end p 14
###begin title 15
3. RESULTS
###end title 15
###begin title 16
3.1. Glucagon response to oral protein
###end title 16
###begin p 17
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 174 175 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 229 230 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 236 237 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 466 467 462 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 776 777 768 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 925 927 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 982 984 969 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 718 733 <span type="species:ncbi:10090">transgenic mice</span>
###xml 770 774 <span type="species:ncbi:10090">mice</span>
###xml 958 962 <span type="species:ncbi:10090">mice</span>
###xml 1006 1021 <span type="species:ncbi:10090">transgenic mice</span>
Figure 1 (upper left panel) shows plasma glucagon levels during the oral protein challenge. Baseline glucagon levels were higher in the transgenic animals (41 +/- 4.0 pg/mL, n = 6) than in the wildtype animals (19 +/- 5.1 pg/mL, n = 5, P = .015). Glucagon levels at 15, 30, and 60 minutes after protein administration did not differ significantly between the groups, whereas the levels after 120 minutes were, again, significantly, higher in the transgenic animals (P = .008). Glucagon secretion was estimated as the change in glucagon levels during the first 15 minutes after protein gavage. This 15-minute glucagon response to protein administration was impaired in the transgenic animals, being 21 +/- 2.7 pg/mL in transgenic mice versus 38 +/- 5.7 pg/mL in wildtype mice (P = .027). The suprapasal AUC for glucagon for the entire 120-minute study period did not differ significantly between the groups, being 4.3 +/- 1.1 mug/mL x 120 minutes in wildtype mice versus 3.9 +/- 0.9 mug/mL x 120 minutes in transgenic mice.
###end p 17
###begin title 18
3.2. Insulin and glucose responses to oral protein
###end title 18
###begin p 19
###xml 375 376 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 386 394 378 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 587 595 575 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 93 108 <span type="species:ncbi:10090">transgenic mice</span>
###xml 110 112 <span type="species:ncbi:10090">NS</span>
###xml 173 188 <span type="species:ncbi:10090">transgenic mice</span>
###xml 504 519 <span type="species:ncbi:10090">transgenic mice</span>
###xml 521 523 <span type="species:ncbi:10090">NS</span>
Baseline insulin levels were 50 +/- 5.1 pamol/L in wildtype animals and 46 +/- 4.9 pmol/L in transgenic mice (NS). The insulin response to protein ingestion was impaired in transgenic mice; the suprabasal AUC for insulin for the 120-minute study period was 27.2 +/- 3.1 nmol/L x 120 minutes in wildtype animals versus 16.5 +/- 3.9 nmol/L x 120 minutes in transgenic animals (P = .018) (Figure 1, upper right). Baseline glucose levels were 7.2 +/- 0.3 mmol/L in wildtype animals and 7.8 +/- 0.2 mmol/L in transgenic mice (NS); glucose levels did not change significantly during the test (Figure 1, lower left panel).
###end p 19
###begin title 20
3.3. Acetaminophen response to acetaminophen administration
###end title 20
###begin p 21
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
Figure 1 (lower right) shows the acetaminophen concentrations during test. Plasma acetaminophen increased to a maximum level at 15 minutes after administration, thereafter it gradually fell. There was no significant difference between the groups in plasma acetaminophen.
###end p 21
###begin title 22
4. DISCUSSION
###end title 22
###begin p 23
###xml 88 92 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 345 347 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 902 907 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 940 944 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 1052 1054 1042 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1376 1377 1366 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1378 1380 1368 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 203 218 <span type="species:ncbi:10090">transgenic mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 410 425 <span type="species:ncbi:10090">transgenic mice</span>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 788 792 <span type="species:ncbi:10090">mice</span>
###xml 850 854 <span type="species:ncbi:10090">mice</span>
This study evaluated the islet hormone responses to oral protein ingestion in mice with beta-cell specific overexpression of human IAPP. It was found that the insulin response to protein was impaired in transgenic mice. This confirms that these mice have impaired insulin secretion, as previously was reported also after oral glucose challenge [15]. The main novel finding in this report is, however, that the transgenic mice have also changes in the glucagon levels. Thus, the mice were found to have higher baseline glucagon levels than their wildtype counterparts and yet they have a reduced glucagon response to protein administration. The mechanism of the high-baseline glucagon remains to be established. It is, however, consistent with the disturbance in islet topography in these mice. Thus, we have previously shown that the islets of these mice have enlarged population of glucagon producing alpha cells as opposed to the reduced beta-cell immunostaining in these animals which is associated with significantly reduced islet insulin content [16]. This hyperglucagonemia may be the result of the reduced islet insulin, in view of the inhibitory influence of insulin on glucagon secretion. At the same time, the glucagon response to the protein administration was impaired, which may be explained by the transgene, because IAPP is known to inhibit glucagon secretion [8-11]. Hence, high-baseline glucagon and impaired glucagon response to stimulation are two characteristics of the hIAPP transgene, and may have different mechanisms.
###end p 23
###begin p 24
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 971 975 971 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 163 178 <span type="species:ncbi:10090">transgenic mice</span>
###xml 431 437 <span type="species:ncbi:9606">humans</span>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
###xml 933 937 <span type="species:ncbi:10090">mice</span>
###xml 1104 1108 <span type="species:ncbi:10090">mice</span>
In this study, we also determined the acetaminophen concentration after acetaminophen administration to determine whether gastric emptying had been altered in the transgenic mice. Previously, inhibition by IAPP of gastric emptying has been demonstrated [11] and changes in gastric emptying would be a mechanism for changes in glucagon secretion after protein administration. The acetaminophen test has previously been validated in humans [20] and used in a previous study in mice [17]. It is based on the poor absorption of acetaminophen from the stomach and the rapid and almost complete absorption from the small intestine. This implies that plasma acetaminophen profiles give an estimation of gastric emptying, which also has been verified as good correlation with isotopic technique measurements of gastric emptying [21, 22]. We found that there was no difference in plasma acetaminophen profiles between transgenic and wildtype mice. This shows that the increase in beta-cell IAPP expression does not affect gastric emptying, and, therefore, the inhibited glucagon response to oral protein in these mice is not due to impaired gastric emptying.
###end p 24
###begin p 25
###xml 41 45 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 249 254 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 349 353 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 369 371 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 373 375 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 78 83 <span type="species:ncbi:9606">human</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
In conclusion, this study has shown that beta-cell specific overexpression of human IAPP increases baseline glucagon levels and impairs the glucagon response to oral protein in association with impaired insulin response. This shows that a disturbed alpha-cell function in these mice is evident in association with the previously described disturbed beta-cell function [15, 16].
###end p 25
###begin title 26
ACKNOWLEDGMENTS
###end title 26
###begin p 27
The authors are grateful to Kristina Andersson, Lilian Bengtsson, and Lena Kvist for expert technical assistance. This study was supported by the Swedish Research Council (Grants 6834), The Swedish Diabetes Foundation, Albert Pahlsson Foundation, The Swedish Diabetes Association, Region Skane, and the Faculty of Medicine, Lund University.
###end p 27
###begin article-title 28
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 77 80 <span type="species:ncbi:9685">cat</span>
Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells
###end article-title 28
###begin article-title 29
Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas
###end article-title 29
###begin article-title 30
IAPP as a regulator of glucose homeostasis and pancreatic hormone secretion (review)
###end article-title 30
###begin article-title 31
###xml 81 87 <span type="species:ncbi:9606">humans</span>
Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans
###end article-title 31
###begin article-title 32
###xml 20 23 <span type="species:ncbi:10116">rat</span>
###xml 114 118 <span type="species:ncbi:10116">rats</span>
Effects of amidated rat islet amyloid polypeptide on glucose-stimulated insulin secretion in vivo and in vitro in rats
###end article-title 32
###begin article-title 33
###xml 100 103 <span type="species:ncbi:10116">rat</span>
Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas
###end article-title 33
###begin article-title 34
###xml 66 70 <span type="species:ncbi:10116">rats</span>
Islet amyloid polypeptide inhibits insulin secretion in conscious rats
###end article-title 34
###begin article-title 35
###xml 54 58 <span type="species:ncbi:10116">rats</span>
Dose-response for glucagonostatic effect of amylin in rats
###end article-title 35
###begin article-title 36
###xml 43 47 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 50 55 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 62 67 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 95 98 <span type="species:ncbi:10116">rat</span>
Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets
###end article-title 36
###begin article-title 37
Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets
###end article-title 37
###begin article-title 38
###xml 72 76 <span type="species:ncbi:10116">rats</span>
Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187
###end article-title 38
###begin article-title 39
Islet amyloid polypeptide: mechanisms of amyloidogenesis in the pancreatic islets and potential roles in diabetes mellitus
###end article-title 39
###begin article-title 40
Islet amyloid and type 2 diabetes mellitus
###end article-title 40
###begin article-title 41
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 124 129 <span type="species:ncbi:9606">human</span>
Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets
###end article-title 41
###begin article-title 42
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice
###end article-title 42
###begin article-title 43
###xml 166 170 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 203 208 <span type="species:ncbi:9606">human</span>
DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide
###end article-title 43
###begin article-title 44
###xml 111 115 <span type="species:ncbi:10090">mice</span>
Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice
###end article-title 44
###begin article-title 45
###xml 57 72 <span type="species:ncbi:10090">transgenic mice</span>
###xml 113 118 <span type="species:ncbi:9606">human</span>
Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide
###end article-title 45
###begin article-title 46
###xml 0 4 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
beta-Cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes
###end article-title 46
###begin article-title 47
Gastric emptying: comparison of scintigraphic, polyethylene glycol dilution, and paracetamol tracer assessment techniques
###end article-title 47
###begin article-title 48
###xml 61 64 <span type="species:ncbi:9606">man</span>
Kinetics of acetaminophen absorption and gastric emptying in man
###end article-title 48
###begin article-title 49
Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics
###end article-title 49
###begin p 50
###xml 162 163 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 194 198 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 238 239 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 354 355 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 173 188 <span type="species:ncbi:10090">transgenic mice</span>
Plasma levels of glucagon, insulin, glucose, and acetaminophen following administration of whey protein (75 mg) and acetaminophen (2 mg) in female wildtype mice (n = 5) and transgenic mice with beta-cell specific overexpression of hIAPP (n = 6). Means +/- SEM are shown. Asterisks indicate probability level of random difference between the two groups (*P < .05).
###end p 50

